211 related articles for article (PubMed ID: 26052612)
21. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
22. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
[TBL] [Abstract][Full Text] [Related]
23. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
25. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
26. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
[TBL] [Abstract][Full Text] [Related]
27. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
29. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).
Addis A; Loebstein R; Koren G; Einarson TR
Eur J Clin Pharmacol; 1999 Mar; 55(1):1-6. PubMed ID: 10206077
[TBL] [Abstract][Full Text] [Related]
30. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
Antmen B; Karakaş Z; Yeşilipek MA; Küpesiz OA; Şaşmaz İ; Uygun V; Kurtoğlu E; Oktay G; Aydogan G; Akın M; Salcioglu Z; Vergin C; Kazancı EG; Ünal S; Çalışkan Ü; Aral YZ; Türkkan E; Meral Güneş A; Tunç B; Gümrük F; Ayhan AC; Söker M; Koç A; Oymak Y; Ertem M; Timur Ç; Yıldırmak Y; İrken G; Apak H; Biner B; Eren TG; Işık Balcı Y; Koçak Ü; Karasu G; Akkaynak D; Patıroğlu T
Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
[TBL] [Abstract][Full Text] [Related]
31. Correlation between liver iron concentration determined by magnetic resonance imaging and serum ferritin in adolescents with thalassaemia disease.
Chuansumrit A; Laothamathat J; Sirachainan N; Sungkarat W; Wongwerawattanakoon P; Kumkrua P
Paediatr Int Child Health; 2016 Aug; 36(3):203-8. PubMed ID: 27595699
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients.
Akrawinthawong K; Chaowalit N; Chatuparisuth T; Siritanaratkul N
Hematology; 2011 Mar; 16(2):113-22. PubMed ID: 21418744
[TBL] [Abstract][Full Text] [Related]
33. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
Fragomeno C; Roccabruna E; D'Ascola DG
Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
[TBL] [Abstract][Full Text] [Related]
34. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
35. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Kwiatkowski JL; Hamdy M; El-Beshlawy A; Ebeid FSE; Badr M; Alshehri A; Kanter J; Inusa B; Adly AAM; Williams S; Kilinc Y; Lee D; Tricta F; Elalfy MS
Blood Adv; 2022 Feb; 6(4):1243-1254. PubMed ID: 34847228
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
Gomber S; Saxena R; Madan N
Indian Pediatr; 2004 Jan; 41(1):21-7. PubMed ID: 14767084
[TBL] [Abstract][Full Text] [Related]
38. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study.
Taher A; Sheikh-Taha M; Sharara A; Inati A; Koussa S; Ellis G; Dhillon AP; Hoffbrand AV
Acta Haematol; 2005; 114(3):146-9. PubMed ID: 16227677
[TBL] [Abstract][Full Text] [Related]
39. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Hamdy M; El-Beshlawy A; Veríssimo MPA; Kanter J; Inusa B; Williams S; Lee D; Temin NT; Fradette C; Tricta F; Ebeid FSE; Kwiatkowski JL; Elalfy MS
Pediatr Blood Cancer; 2024 Jan; 71(1):e30711. PubMed ID: 37807937
[TBL] [Abstract][Full Text] [Related]
40. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]